×
About 583 results

ALLMedicine™ Prurigo Nodularis Center

Research & Reviews  275 results

Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A R...
https://doi.org/10.1016/j.jaad.2021.02.038
Journal of the American Academy of Dermatology; Georgakopoulos JR, Croitoru D et. al.

Feb 22nd, 2021 - Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A Retrospective Cohort Study.|2021|Georgakopoulos JR,Croitoru D,Felfeli T,Alhusayen R,Lansang P,|

Real-world disease burden and comorbidities of pediatric prurigo nodularis.
https://doi.org/10.1016/j.jaad.2021.02.030
Journal of the American Academy of Dermatology; Huang AH, Roh YS et. al.

Feb 18th, 2021 - Real-world disease burden and comorbidities of pediatric prurigo nodularis.|2021|Huang AH,Roh YS,Sutaria N,Choi J,Williams KA,|

Dupilumab as promising treatment for prurigo nodularis: current evidences.
https://doi.org/10.1080/09546634.2021.1886232
The Journal of Dermatological Treatment; Toffoli L, Farinazzo E et. al.

Feb 16th, 2021 - Prurigo nodularis (PN) is a debilitating chronic disease characterized by intense itching and excoriated hyperkeratotic nodules distributed on the trunk and extremities, especially the extensor surfaces. The pathophysiology includes complex and no...

Dupilumab treatment of prurigo nodularis in an adolescent.
https://doi.org/10.1684/ejd.2020.3947
European Journal of Dermatology : EJD; Giovannini M, Mori F et. al.

Feb 15th, 2021 - Dupilumab treatment of prurigo nodularis in an adolescent.|2021|Giovannini M,Mori F,Oranges T,Ricci S,Barni S,|

Prurigo nodularis comparative treatment outcome in patients attending a tertiary hospit...
https://doi.org/10.1111/dth.14855
Dermatologic Therapy; Mayala EV, Mavura DR et. al.

Feb 9th, 2021 - Prurigo nodularis (PN) is a chronic, benign neurodermatitis of unclear etiology characterized by excoriated, intensely pruritic nodules secondary to an intense itch-scratch cycle. PN treatment is still a challenge, and it is frustrating for both d...

see more →

Clinicaltrials.gov  285 results

Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A R...
https://doi.org/10.1016/j.jaad.2021.02.038
Journal of the American Academy of Dermatology; Georgakopoulos JR, Croitoru D et. al.

Feb 22nd, 2021 - Long-term Dupilumab Treatment for Chronic Refractory Generalized Prurigo Nodularis: A Retrospective Cohort Study.|2021|Georgakopoulos JR,Croitoru D,Felfeli T,Alhusayen R,Lansang P,|

Real-world disease burden and comorbidities of pediatric prurigo nodularis.
https://doi.org/10.1016/j.jaad.2021.02.030
Journal of the American Academy of Dermatology; Huang AH, Roh YS et. al.

Feb 18th, 2021 - Real-world disease burden and comorbidities of pediatric prurigo nodularis.|2021|Huang AH,Roh YS,Sutaria N,Choi J,Williams KA,|

Dupilumab as promising treatment for prurigo nodularis: current evidences.
https://doi.org/10.1080/09546634.2021.1886232
The Journal of Dermatological Treatment; Toffoli L, Farinazzo E et. al.

Feb 16th, 2021 - Prurigo nodularis (PN) is a debilitating chronic disease characterized by intense itching and excoriated hyperkeratotic nodules distributed on the trunk and extremities, especially the extensor surfaces. The pathophysiology includes complex and no...

Dupilumab treatment of prurigo nodularis in an adolescent.
https://doi.org/10.1684/ejd.2020.3947
European Journal of Dermatology : EJD; Giovannini M, Mori F et. al.

Feb 15th, 2021 - Dupilumab treatment of prurigo nodularis in an adolescent.|2021|Giovannini M,Mori F,Oranges T,Ricci S,Barni S,|

Prurigo nodularis comparative treatment outcome in patients attending a tertiary hospit...
https://doi.org/10.1111/dth.14855
Dermatologic Therapy; Mayala EV, Mavura DR et. al.

Feb 9th, 2021 - Prurigo nodularis (PN) is a chronic, benign neurodermatitis of unclear etiology characterized by excoriated, intensely pruritic nodules secondary to an intense itch-scratch cycle. PN treatment is still a challenge, and it is frustrating for both d...

see more →

News  23 results

Nemolizumab tames itching in prurigo nodularis patients in phase 2 study
https://www.mdedge.com/dermatology/article/217918/medical-dermatology/nemolizumab-tames-itching-prurigo-nodularis-patients?channel=39212
Heidi Splete

Feb 26th, 2020 - Adults with moderate to severe prurigo nodularis who were treated with the investigational drug nemolizumab showed significant improvement in itching, compared with patients treated with placebo, according to data from a phase 2 trial of 70 patien.

Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis
https://www.staging.medscape.com/viewarticle/925465

Feb 20th, 2020 - NEW YORK (Reuters Health) - An experimental treatment for prurigo nodularis (PN) can reduce itching by 53% over four weeks, according to a phase-2 test of subcutaneous nemolizumab. The reduction was only 20% with placebo therapy. However, the impr...

Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis
https://www.medscape.com/viewarticle/925465

Feb 20th, 2020 - NEW YORK (Reuters Health) - An experimental treatment for prurigo nodularis (PN) can reduce itching by 53% over four weeks, according to a phase-2 test of subcutaneous nemolizumab. The reduction was only 20% with placebo therapy. However, the impr...

Rapid improvement seen with nemolizumab for prurigo nodularis in phase 2b study
https://www.mdedge.com/dermatology/article/211733/medical-dermatology/rapid-improvement-seen-nemolizumab-prurigo-nodularis?channel=39313
Bruce Jancin

Nov 6th, 2019 - MADRID – Nemolizumab, an investigational humanized monoclonal antibody targeting the interleukin-31 receptor alpha subunit, achieved rapid and clinically meaningful improvement in both itch and skin lesions of severe prurigo nodularis in a phase 2.

Serlopitant quells prurigo nodularis in phase 2 study
https://www.mdedge.com/dermatology/article/178171/medical-dermatology/serlopitant-quells-prurigo-nodularis-phase-2-study
Bruce Jancin

Oct 26th, 2018 - PARIS – The investigational oral neurokinin-1 receptor antagonist serlopitant significantly reduced multiple distressing sensory symptoms of prurigo nodularis in a 127-patient, randomized, placebo-controlled trial, Sonja Stander, MD, said at the a.

see more →